BR9808769A - Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio - Google Patents

Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio

Info

Publication number
BR9808769A
BR9808769A BR9808769-0A BR9808769A BR9808769A BR 9808769 A BR9808769 A BR 9808769A BR 9808769 A BR9808769 A BR 9808769A BR 9808769 A BR9808769 A BR 9808769A
Authority
BR
Brazil
Prior art keywords
mammalian host
gene
site
cell
paired
Prior art date
Application number
BR9808769-0A
Other languages
English (en)
Inventor
Stephen Charles Emery
David Charles Blakey
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of BR9808769A publication Critical patent/BR9808769A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • External Artificial Organs (AREA)

Abstract

''CONSTRUçãO DE GENE, USO DE UMA CONSTRUçãO DE GENE, SISTEMA DE DOIS COMPONENTES EMPARELHADOS, DESIGNADO PARA O USO EM UM HOSPEDEIRO MAMìFERO, E, PROCESSO PARA TRANSFERêNCIA DE UM MEDICAMENTO CITOTóXICO PARA UM SìTIO". A invenção fornece uma construção de gene que codifica uma porção alvo de célula e uma enzima heteróloga ativadora de pró-medicamento para o uso como um medicamento em um hospedeiro mamífero em que a construção de gene é capaz de expressar a porção alvo de célula e a enzima como um conjugado dentro de uma célula alvo no hospedeiro mamífero e em que o conjugado é direcionado para deixar a célula depois disso para a localização seletiva em um antígeno de superfície celular reconhecido pela porção alvo de célula.
BR9808769-0A 1997-05-10 1998-05-05 Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio BR9808769A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709421.3A GB9709421D0 (en) 1997-05-10 1997-05-10 Chemical compounds
PCT/GB1998/001294 WO1998051787A2 (en) 1997-05-10 1998-05-05 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety

Publications (1)

Publication Number Publication Date
BR9808769A true BR9808769A (pt) 2000-08-01

Family

ID=10812048

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808769-0A BR9808769A (pt) 1997-05-10 1998-05-05 Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio

Country Status (23)

Country Link
US (1) US6339070B1 (pt)
EP (1) EP0979292B1 (pt)
JP (1) JP2001526539A (pt)
KR (1) KR100508136B1 (pt)
CN (1) CN1268743C (pt)
AT (1) ATE412755T1 (pt)
AU (1) AU734915B2 (pt)
BR (1) BR9808769A (pt)
CA (1) CA2286875A1 (pt)
DE (1) DE69840165D1 (pt)
ES (1) ES2314990T3 (pt)
GB (2) GB9709421D0 (pt)
HU (1) HUP0001931A3 (pt)
IL (1) IL132348A0 (pt)
MY (1) MY140975A (pt)
NO (1) NO995475L (pt)
NZ (1) NZ500014A (pt)
PL (1) PL337007A1 (pt)
RU (1) RU2218404C2 (pt)
SK (1) SK153599A3 (pt)
TR (1) TR199902731T2 (pt)
WO (1) WO1998051787A2 (pt)
ZA (1) ZA983931B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910077D0 (en) 1999-05-01 1999-06-30 Univ Manchester Chemical compounds
DE19946142A1 (de) * 1999-09-27 2001-03-29 Bundesrepublik Deutschland Let Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
WO2003104425A2 (en) * 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
US20050107320A1 (en) * 2003-01-30 2005-05-19 Matthew During Methods and compositions for use in interventional pharmacogenomics
HUE033533T2 (en) 2003-04-30 2017-12-28 Universität Zuerich A method of treating cancer using immunotoxin
JP4982183B2 (ja) * 2003-12-12 2012-07-25 ジェネンコー・インターナショナル・インク Ｃａｂ分子
NZ550665A (en) 2004-04-09 2010-05-28 Chugai Pharmaceutical Co Ltd Novel water-soluble prodrugs of camptothecin derivatives
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2633756C (en) * 2005-12-21 2015-11-24 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
US8263744B2 (en) * 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
CA2700815A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
WO2010019257A2 (en) * 2008-08-13 2010-02-18 The Johns Hopkins University Prodrug activation in cancer cells using molecular switches
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
EP3559049A4 (en) * 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
ES2703052T3 (es) 2012-08-03 2019-03-06 Cedars Sinai Medical Center Aislamiento de mutantes potenciadores del tráfico de proteína de entrega de fármacos
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
CN108513547A (zh) 2015-03-12 2018-09-07 维文蒂亚生物公司 用于epcam阳性膀胱癌的治疗方法
KR20230003478A (ko) 2020-03-24 2023-01-06 제너레이션 바이오 컴퍼니 비-바이러스성 dna 벡터 및 고셰 치료제 발현을 위한 이의 용도
CN115667530A (zh) 2020-03-24 2023-01-31 世代生物公司 非病毒dna载体和其用于表达因子ix治疗剂的用途
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
JPH08504091A (ja) 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9323008D0 (en) 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9423367D0 (en) 1994-11-18 1995-01-11 Wellcome Found Enzyme prodrug therapy
JP3805365B2 (ja) * 1994-12-23 2006-08-02 シンジェンタ リミテッド 化合物
AU707689B2 (en) * 1995-08-16 1999-07-15 Astrazeneca Ab Mutated Carboxypeptidase B enzyme conjugated to a tumour targeted antibody for use in Antibody Directed Enzyme Prodrug Therapy
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
GB9601640D0 (en) 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
EP1012259B1 (en) 1997-06-04 2009-09-30 Oxford Biomedica (UK) Limited Tumor targeted vector

Also Published As

Publication number Publication date
IL132348A0 (en) 2001-03-19
HUP0001931A2 (hu) 2000-09-28
ES2314990T3 (es) 2009-03-16
GB2338484B (en) 2001-11-07
CN1255163A (zh) 2000-05-31
EP0979292B1 (en) 2008-10-29
ATE412755T1 (de) 2008-11-15
AU7225498A (en) 1998-12-08
GB9709421D0 (en) 1997-07-02
AU734915B2 (en) 2001-06-28
WO1998051787A2 (en) 1998-11-19
CA2286875A1 (en) 1998-11-19
GB9922815D0 (en) 1999-11-24
DE69840165D1 (de) 2008-12-11
NO995475D0 (no) 1999-11-09
WO1998051787A3 (en) 1999-04-01
CN1268743C (zh) 2006-08-09
SK153599A3 (en) 2000-06-12
GB2338484A (en) 1999-12-22
NZ500014A (en) 2001-08-31
HUP0001931A3 (en) 2003-10-28
JP2001526539A (ja) 2001-12-18
EP0979292A2 (en) 2000-02-16
NO995475L (no) 2000-01-07
KR20010012441A (ko) 2001-02-15
TR199902731T2 (xx) 2000-06-21
ZA983931B (en) 1998-11-10
RU2218404C2 (ru) 2003-12-10
MY140975A (en) 2010-02-12
PL337007A1 (en) 2000-07-31
KR100508136B1 (ko) 2005-08-10
US6339070B1 (en) 2002-01-15

Similar Documents

Publication Publication Date Title
BR9808769A (pt) Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio
BR0015501A (pt) Compostos de aminoalquil glucosaminida fosfato e uso dos mesmos como adjuvantes e agentes de efeito imune
BR9912587A (pt) Processo sistema e dispositivo para realçar a absorção celular de uma substância, processos para realçar a transfecção de gene de um gene transferido para uma região alvo do corpo de um paciente e para promover a angiogênese em membros isquêmicos, e, kit
BR9809791A (pt) Compostos de fosfato de aminoalquil glucosamina e seu uso como auxiliares e imuno efetores
ES2191749T3 (es) Utilizacion de aerogeles inorganicos en farmacia.
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
BR9712988A (pt) Imunoterapia do câncer usando células tumorais combinadas com mistura de linfócitos
ID22689A (id) Metode untuk mengaktifkan sel-sel yang menunjukan-sifat antigen manusia, sel-sel teraktifkan yang menunjukan sifat antigen manusia, dan penggunaannya
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
ATE363533T1 (de) Osteoprotegerin bindende proteine und rezeptoren
BR0110610A (pt) Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
ES2161246T3 (es) Factor transformante de crecimiento alfa h1.
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
CY1106110T1 (el) ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΕΝΟΣ ΠΕΠΤΙΔΙΟΥ ΜΕ pI ΠΑΝΩ ΑΠΟ 8 Ή ΚΑΤΩ ΑΠΟ 5
AR022236A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
Premont et al. Specific Mg2+ and adenosine sites involved in a bireactant mechanism for adenylate cyclase inhibition and their probable localization on this enzyme's catalytic component
AR017887A1 (es) Estructuras artificiales de acidos nucleicos, procedimiento para su preparacion, celula aislada y uso de dichas estructuras y dicha celula para lamanufactura de un medicamento
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
AR022237A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
AU8239298A (en) Nucleotide-comprising composition
NO20014537D0 (no) AKT-nukleinsyrer, -polypeptider og anvendelse av disse
DE69528170D1 (de) Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
BR0015597A (pt) Uso de anticorpos como vacinas
EE200000538A (et) TNF/NGF retseptoriperekonna retseptorite ja muudevalkude talitluse modulaatorid, nende valmistamine ja kasutamine ning farmatseutiline kompositsioon

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SYNGENTA LIMITED (GB)

Free format text: ALTERADO DE: ZENECA LIMITED

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA UK LIMITED (GB)

Free format text: TRANSFERIDO DE: SYNGENTA LIMITED

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1937 DE 19/02/2008